Denali Therapeutics Inc. is looking to raise up to $303.5 million in an IPO of up to 13,888,888 shares priced anywhere between $17 per share and $19 per share.
The company has applied to list its common stock on the Nasdaq Global Select Market under the symbol DNLI.
The early clinical-stage biopharmaceutical company also offered its underwriters the option to purchase up to an additional 2,083,333 shares at the initial public offering price.
Denali Therapeutics is focused on developing therapeutics for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.
The company said certain of its existing stockholders have indicated they may buy at least $50 million of the shares offered.
Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC and Evercore Group LLC will act as underwriters for the offering.